BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers; and APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.…
BioLineRx to Report Third Quarter 2026 Results on November 23, 2026
BioLineRx Enters into $5.6 Million Royalty Monetization Transaction with Soleus Capital
BioLineRx (NASDAQ: BLRX) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 20 employees.
The shares were at 0.9639 USD on 20 November 2026, down 72.3% over 52 weeks. Its 52-week range is 0.7800 USD to 3.950 USD: the price is 75.6% below the high and 23.6% above the low.
Its market capitalisation is 4.80M USD.
BioLineRx reports return on equity of -6.5% and revenue down 3.3% year over year.
It holds more cash than debt, a net cash position of 5.14M USD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. The next earnings report is expected on 23 November 2026.